In-vitro evaluation of the PALL Leukotrap affinity prion reduction filter as a secondary device following primary leucoreduction

Vox Sanguinis

Volumn 89, Issue 4, 2005, Pages 220-228

  Saunders, C ^a   Herbert, P ^a   Rowe, G ^a   Hayward, M ^a   Wilkins, K ^b   Milligan, J ^b   Stenning, M ^b   Seacombe, A ^b   Prowse, C ^c  

^a Welsh Blood Service   (United Kingdom)

^b Pall Medical   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

In vitro evaluation; Prion reduction; Red cells; Storage studies

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; COMPLEMENT COMPONENT C3A; GLUCOSE; HEMOGLOBIN; LACTIC ACID; POTASSIUM; PRION PROTEIN; SODIUM;

ARTICLE; BLOOD SAMPLING; CARBON DIOXIDE TENSION; CENTRIFUGATION; CONTROLLED STUDY; DEVICE; DISEASE TRANSMISSION; ERYTHROCYTE LEVEL; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; FILTER; HEMATOCRIT; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; OXYGEN TENSION; PH; PRION DISEASE; PRIORITY JOURNAL; UNITED KINGDOM;

ERYTHROCYTE TRANSFUSION; HEMOFILTRATION; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; PLASMA; PRPC PROTEINS;

EID: 27844526948     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2005.00703.x     Document Type: Article

References (38)

1. Collinge J: Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001; 24:519-520
2. Department of Health: Monthly Creuzfeldt Jakob Disease Statistics. http://dh.gov.uk/PublictionsandStatistics/PressReleasesNotices/frs/en?CONTENTS 1 November 2004 (8 November 2004)
3. Will RG, Ironside JW, Zeidler M: A new variant of Creuzfeldt-Jakob disease in the UK. Lancet 1996; 347:921-925
4. Williamson L: Leucocyte depletion of the blood supply - how will patients benefit? Br J Haematol 2000; 110:256-272
5. Boulton F: The impact of variant CJD on transfusion practices in the UK. Transfus Apheresis Sci 2003; 28:107-116
6. Ironside JW, Head MW: Variant Creutzfeldt-Jakob disease and its transmission by blood. J Thromb Haemost 2003; 1:1479-1486
7. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ: Transmission of BSE by blood transfusion in sheep. Lancet 2000; 16:999-1000
8. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83:2897-2905
9. Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Couesens S, Mackenzie J, Will RG: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417-421
10. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527-529
11. Brown P, Rowher RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN: The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38:810-816
12. Brown P, Cervenakova LM, McShane LM, Barber P, Rubenstein R, Drohan WN: Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
13. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShaen L, Drohan WN, Brown P: Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encaphalopathy. Transfusion 2003; 43:1687-1694
14. Gregori L, McCombie N, Palmer D, Birch P, Sowemino-Coker SO, Giulivi A, Rowher RG: Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encaphalopathies from blood. Lancet 2004; 364:529-531
15. Holada K, Vostal JG, Patrick PW, MacAuley C, Gregori L, Rowher RG: Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002; 76:4649-4650
16. Department of Health: Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products, http://dnv.com/binaries/vCJD_Update_Report_tcm4-74414. pdf 2003 (10 December 2004)
17. Agence Francaise de Securite Sanitaire des Produits de Sante: Expert Group on Risk of TSE Transmission via Blood Products. Report December 11, 2000
18. Minor PD: Technical aspects of the development and validation of tests for variant Creutzfeldt-Jacob disease in blood transfusion. Vox Sang 2004; 86:164-170
19. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D: Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203:733-739
20. Frosh A, Smith LC, Jackson CJ, Linehan JM, Brandner S, Wadsworth JDF, Collinge J: Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein, Lancet 2004; 364:1260-1262
21. Prowse CV, Hornsey VS, Drummond O, MacGregor R, Pepper DS, Barclay GR, Bethel H, Walker B, Barnard G, Kirby L, Hope J: Preliminary assessment of whole-blood, red-cell and platelet-leucocyte depleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing. Br J Haematol 1999; 106:240-247
22. Prowse CV, Bailey A: Validation of prion removal by leucocyte depleting filters: a cautionary tale. Vox Sang 2000; 79:248
23. Sowemimo-Coker SO, Kim A, Zinn F, Madraswalla F, Chiang A, Kascsak RB, Kascsak RJ, Meeker HC, Carp RI: Removal of infectious prion from naturally occurring infected red blood cell concentrates. Vox Sang 2004; 87 (suppl. 3):10
24. BS 5736: Evaluation of Medical Devices for Biological Hazards. Part II. Method for Test for Haemolysis. London, BSI, 1990
25. Lundin A: Use of firefly luciferase in ATP-related assays of biomass, enzymes and metabolites. Methods Enzymol 2000; 305:346-370
26. MacGregor I, Hope J, Barnard G, Kirby L, Drummond O, Pepper D, Hornsey V, Barclay R, Bessos H, Turner M, Prowse C: Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999; 77:88-96
27. Council of Europe Publishing: Guide to the Preparation, Use and Quality Assurance of Blood Components, 10th edn. Strasbourg, Council of Europe Publishing, 2004
28. Virge J (ed): Guidelines for the Blood Transfusion Services in the United Kingdom, 6th edn. Norwich, The Stationary Office (TSO), 2002
29. Anon: UK Specialist Advisory Committee for Blood Components Technical Group, 2004
30. Serious hazards of transfusion (SHOT): http://www.shotuk.org/ (20th June 2005)
31. Heaton WAL, Holme S, Smith K, Brecher ME, Pineda A, AuBuchon JP, Nelson E: Effects of 3-5 log 10 pre-storage leucocyte depletion on red cell storage and metabolism. Br J Haematol 1994;87:363-368
32. Pietersz RNI, de Korte D, Reesink HW, Dekker WJA, van den Ende A, Loos JA: Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989; 56:145-150
33. Hogman CF: Liquid-stored red blood cells for transfusion. Vox Sang 1999; 76:67-77
34. Hess JR, Kagen LR, van der Meer PF, Simon T, Cardigan R, Greenwalt TJ, AuBuchon JP, Brand A, Lockwood W, Zanella A, Adamson J, Snyder E, Taylor HL, Moroff G, Hogman C: Interlaboratory comparison of red-cell ATP, 2,3-diphosphoglycerate and haemolysis measurements. Vox Sang 2005; 89:44-48
35. Mollnes TE, Garred P, Bergseth G: Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988; 73:484-488
36. Hetland G, Mollnes TE, Larsen J, Garred P: Biocompatibility of white cell filters as evaluated by complement activation. Transfusion 1992;32:557-561
37. Cardigan R, Sutherland J, Garwood M, Krailadsiri P, Segatchian J, Beard M, Beckman N, Williamson L: The effect of leucocyte depletion on the quality of fresh frozen plasma. Br J Haematol 2001; 114:233-240
38. Nelson E, Taylor H, Whitley P, Lieu T: Evaluation of in vivo red blood cell recovery after processing with a new filter designed to remove prions. Vox Sang 2005; 89:44-48